20/20 Biolabs Inc. (AIDX) vs Lexaria Bioscience Corp. (LEXX)
A side-by-side comparison of 20/20 Biolabs Inc. and Lexaria Bioscience Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AIDX
20/20 Biolabs Inc.
$0.35HealthcareDelayed quote: Oct 6, 2026, 1:02 PM EDT
LEXX
Lexaria Bioscience Corp.
$2.89HealthcareDelayed quote: Oct 6, 2026, 12:59 PM EDT
Total return — AIDX vs LEXX
growth of $100 · dividends reinvested · last 1yAIDX -98.5% (-98.5%/yr)LEXX -72.0% (-72.0%/yr)LEXX compounded faster over this window
Log scale — wide-divergence pair
AIDX LEXX
AIDX vs LEXX: by the numbers
- •LEXX is the larger company ($5M vs $4M market cap).
- •Both run net losses; AIDX's is the smaller (-285.00% vs -3985.58% net margin).
- •LEXX grew revenue faster over the past five years (12.92% vs -2.58% CAGR).
Metrics side by side
Valuation
| Metric | AIDX | LEXX |
|---|---|---|
| P/S ratio | 2.07 | 24.62 |
| P/B ratio | 2.61 | 1.01 |
Profitability
| Metric | AIDX | LEXX |
|---|---|---|
| Gross margin | 31.52% | 100.00% |
| Operating margin | -162.87% | -1683.01% |
| Net margin | -285.00% | -3985.58% |
| ROE | -184.04% | -163.18% |
| ROIC | -116.89% | -175.26% |
Growth (annualized)
| Metric | AIDX | LEXX |
|---|---|---|
| Revenue CAGR (5Y) | -2.58% | 12.92% |
| Total return CAGR (5Y) | N/A | -50.86% |
Frequently asked
- Which has grown faster, AIDX or LEXX?
- Over the past five years, LEXX grew revenue faster — AIDX at a -2.58% CAGR versus LEXX at 12.92%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.